mycophenolate sodium / Generic mfg. - LARVOL DELTA

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Jul 2026 ➔ Jan 2027 | Trial primary completion date: Jul 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

Performance Review of Emergency Care Management Plans Pre- and Post-Implementation of Electronic Records. (PubMed, Emerg Med Australas) - "ECMPs effectively reduced both the frequency and duration of ED visits. Further research is needed to explore patient experience and other outcome measures."

Journal • Observational data • Retrospective data

ALLOGENEIC ISLET TRANSPLANTATION FOR DIABETIC PATIENT POST-KIDNEY TRANSPLANT DIABETES IN 3 CASES (IPITA 2025) - "Postoperatively, rATG (1 case) or Simulect (2 cases) was administered for immune induction...Anti-inflammatory (etanercept), immunomodulatory, and portal pressure-lowering therapies were applied...Steroid-free immunosuppression (cyclosporine + mycophenolate sodium) was maintained, and kidney function remained stable... Portal vein allogeneic islet transplantation is effective and safe for type 2 diabetes, particularly in kidney transplant recipients on long-term immunosuppression. Even with suboptimal islet counts (<300,000 IEQ), favorable outcomes were achieved. rATG induction may reduce graft loss, and low-toxicity immunosuppressive regimens support long-term graft function."

Clinical • Cerebral Hemorrhage • CNS Disorders • Diabetes • Hematological Disorders • Hypoglycemia • Metabolic Disorders • Transplantation • Type 2 Diabetes Mellitus • Vascular Neurology

Post Transplant Diarrhoea in ABO-incompatible Kidney Transplant – A nemesis for patient and nephrologist (ERA 2025) - "His mycophenolate sodium was reduced to 360mg once a day from previous dose of 360mg thrice a day...Tablet Nitazoxanide 500mg twice a day was added... This case highlights the need to finely balance the immunosuppression in post transplant patients especially ABO-incompatible kidney transplant recipients where transplant physicians tend to over immunosuppress the patients. This can sometime lead to viral infections like Noro virus , CMV or other serious infections. This case reinforces the well known fact that Noro Virus is a common cause of post transplant diarrhea(3)."

Clinical • Post-transplantation • Fatigue • Infectious Disease • Transplantation

Enlight-LN Registry: baseline demographics and clinical characteristics of an initial cohort of patients treated with voclosporin for lupus nephritis in the United States (UKKW 2025) - "In the AURORA 1 and AURORA 2 studies, adding voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids led to significantly earlier and greater reductions in proteinuria while maintaining stable estimated glomerular filtration rate (eGFR) for up to 3 years...A total of 107 patients were on concomitant immunosuppression at voclosporin initiation (most commonly, antimalarials, 72.4%; MMF/mycophenolate sodium, 70.7%; belimumab, 13%)... Baseline data on this initial cohort of patients are reflective of the larger LN population in the US, including high percentages of Black and Hispanic and/or Latino patients. Enrollment of additional patients and ongoing data collection will provide valuable insight into the real-world utilization of voclosporin."

Clinical • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease

Cryptosporidium infection in a kidney transplant patient with recent rejection (UKKW 2025) - "For rejection she was treated with three pulses of intravenous methylprednisolone, followed by oral prednisolone 30mg once daily...Cryptosporidium PCR remained positive on stool sample, and Nitazoxanide was restarted...As a result, her myfortic dose was reduced to 360mg three times a day, and prednisolone continued to be tapered...This requires a multidisciplinary approach, particularly collaboration with microbiology colleagues, and close monitoring of symptoms and renal function. The decision to re-biopsy the patient in this case was helpful in planning appropriate changes in immunosuppression to support clearing the infection."

Clinical • Immunology • Infectious Disease • Inflammation • Nephrology • Pain • Renal Disease • Rotavirus Infections • Solid Organ Transplantation • Transplant Rejection • Transplantation • CD4

Orbital RadiothErapy, Sirolimus and Intravenous steroid for Primary Diplopia in Thyroid Eye Disease (RESIDE): a multi-center, double-masked, sham- and placebo-controlled randomized trial (ChiCTR) - P3 | N=60 | Not yet recruiting | Sponsor: Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital; Department of Ophthalmology and Visual Sciences, PWH

New P3 trial • Ophthalmology • Thyroid Eye Disease

From Changing Windshield Washer Fluid to ECMO Support: A Hidden Hazard of the Immunocompromised (ATS 2025) - "With a medical background of hypertension, type 2 diabetes, and ongoing immunosuppression with Myfortic and Tacrolimus—he initially presented to the ER with nonspecific symptoms: profound weakness, difficulty breathing with exertion, chills, persistent cough, and a dwindling appetite, alongside three months of recurring diarrhea...Antibiotic treatment with azithromycin was initiated immediately...Key diagnostic red flags—such as high fever, relative bradycardia, and unexplained GI symptoms—must prompt a high index of suspicion for Legionella. This case underscores the critical need for healthcare providers to consider Legionella in atypical pneumonia cases, especially for immunosuppressed individuals who might encounter this hidden danger in their daily lives."

Cardiovascular • Chronic Cough • Cough • Diabetes • Hematological Disorders • Hypertension • Infectious Disease • Metabolic Disorders • Pain • Pneumonia • Respiratory Diseases • Type 2 Diabetes Mellitus

"HHV-8 Negative" Cutaneous Kaposi's Sarcoma Following Lung Transplantation (ATS 2025) - "He received basiliximab for induction immunosuppression, followed initially by prednisone, tacrolimus, and mycophenolate sodium for maintenance therapy...After diagnosis, his maintenance immunosuppression was modified to include the addition of an mTOR inhibitor (everolimus) with a concurrent reduction in cyclosporine level goals, as well as discontinuation of azathioprine...Figure 1. Violaceous plaques and nodules on the lower extremities."

Chronic Obstructive Pulmonary Disease • Epstein-Barr Virus Infections • Human Immunodeficiency Virus • Immunology • Infectious Disease • Kaposi Sarcoma • Oncology • Pain • Pulmonary Disease • Respiratory Diseases • Sarcoma • Solid Organ Transplantation • Solid Tumor • Transplantation • CD31 • PECAM1

A Global Comparison of Liver Transplant Drug Pricing: US Versus Other G7 Countries and Australia. (PubMed, Transplant Direct) - "Publicly available drug formularies for Canada, the United Kingdom, Japan, France, Germany, Italy, and Australia were used to collect 2024 prices for 8 commonly used liver transplant medications (mycophenolate mofetil, mycophenolate sodium, sirolimus, tacrolimus, Advagraf, Envarsus, everolimus, and cyclosporine). This study demonstrates the significantly greater financial burden that liver transplant patients in the United States face compared with liver transplant patients in 7 other major industrial countries. Future adoption of international reference pricing may help bridge this pricing disparity."

Journal • Pricing • Transplantation

Pharmacodynamic effect of mTOR inhibition-based immunosuppressive therapy on dendritic cell and natural killer cell subsets after renal transplantation. (PubMed, Clin Exp Immunol) - "mTORi selectively suppressed p70S6K phosphorylation in specific DC and NK subtypes. Evaluating p70S6K phosphorylation through phosphoflow cytometry might serve as a clinical applicable method to comprehend immune cell subset-specific effects of mTOR inhibition, providing detailed pharmacodynamic insights for tailoring mTORi therapy on an individual basis."

Journal • PK/PD data • Chronic Kidney Disease • Nephrology • Renal Disease • Transplantation • CD123 • IL3RA • ITGAX • NCAM1

Enteric-coated Mycophenolate Sodium plus hydroxychloroquine therApy versus hydroxychloroquine for the Remission of Proteinuria in IgA Nephropathy (EMSAR-IgAN trial): study protocol for a randomised trial. (PubMed, BMJ Open) - P4 | "Hydroxychloroquine and mycophenolate mofetil (MMF) are two immunosuppressive agents that have recently garnered increased attention among patients with IgA nephropathy in China. The result of this study will be presented and published at international conferences and in scientific journals. ChiCTR2400093530."

Journal • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Renal Disease

A Blood Stem Cell Transplant for Sickle Cell Disease (clinicaltrials.gov) - P1 | N=3 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Mar 2025 ➔ Feb 2026 | Trial primary completion date: Mar 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Anemia • Bone Marrow Transplantation • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • Transplantation • HLA-B • HLA-C • HLA-DRB1

REPLY TO "UPDATE IN CLINICAL SCIENCE: AUTOIMMUNE HEPATITIS": USE OF ENTERIC-COATED MYCOPHENOLATE SODIUM AS A THERAPEUTIC OPTION FOR AUTOIMMUNE HEPATITIS. (PubMed, J Hepatol) - No abstract available

Journal • Autoimmune Hepatitis • Hepatology • Immunology • Inflammation

Tocilizumab in Cardiac Transplantation (clinicaltrials.gov) - P2 | N=385 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Inflammation • Transplantation

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications (clinicaltrials.gov) - P3 | N=102 | Recruiting | Sponsor: Bristol-Myers Squibb | Trial primary completion date: May 2026 ➔ Dec 2030

Trial primary completion date • Transplantation

Tacrolimus Associated Peptic Ulcer Disease Following Lung Transplant (ISHLT 2025) - "We report a case of tacrolimus associated peptic ulceration following lung transplant.Case Report A 68-year-old male with end-stage COPD underwent bilateral lung transplant and was placed on standard triple immunosuppression with tacrolimus, mycophenolate mofetil (MMF) and prednisone...He was switched from MMF to enteric coated mycophenolate sodium (EC-MPS) as well as decrease in the steroid dose to minimize GI symptoms, and treated medically with sucralfate, pantoprazole, and famotidine...Tacrolimus was then transitioned to cyclosporine...A follow up EGD showed a significant reduction of his largest ulcers, and the six month follow up EGD showed complete resolution of the ulcerations. This case reports a rare adverse effect of a commonly used immunosuppressant medication."

Anemia • Chronic Obstructive Pulmonary Disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Neutropenia • Pain • Peptic Ulcer • Respiratory Diseases • Transplantation

Enteric-Coated Mycophenolate Sodium (EC-MPS) Monotherapy for Renal Dysfunction after Liver Transplantation: a Prospective Trial (ChiCTR) - P4 | N=30 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University

New P4 trial • Hepatology • Liver Failure • Nephrology • Renal Disease • Transplantation

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - P2 | N=35 | Completed | Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University | Active, not recruiting ➔ Completed

Trial completion • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Non-Hodgkin’s Lymphoma • Oncology • Plasmacytoma • Transplantation • HLA-B • HLA-C

Refractory Post Transplant Anemia – Parvovirus B19 as an Overlooked Culprit (NKF-SCM 2025) - "Clinical manifestations include anemia with EPO resistance, reticulocytopenia, pure red cell aplasia, fever, rash, arthralgia and pancytopenia.Methods A 51yo heart TXP recipient with CKD due to cardiorenal syndrome underwent a DDRT with Thymoglobulin and Solumedrol followed by Tacrolimus, Mycophenolate and Prednisone...Myfortic was held...Low-grade DNAemia may persist despite recovery.Conclusion Pv is an important cause of early refractory PTA. Early recognition and treatment are key to preventing long-term complications associated with PTA, such as graft failure and mortality."

Post-transplantation • Anemia • Cardiovascular • Chronic Kidney Disease • Fatigue • Hematological Disorders • Musculoskeletal Pain • Nephrology • Transplantation

Persistent norovirus infection in kidney transplant recipient -a management dilemma (NKF-SCM 2025) - "She was maintained on standard immunosuppression (IS) with tacrolimus( levels 6-8 ng/ml), Myfortic 180 mg twice daily and 5mg of prednisone...Current strategies include supportive care, reducing immunosuppression, with possible trial of Nitazoxanide and IVIg that may have limited benefit in specific cases.Conclusion Managing norovirus in kidney transplant setting calls for a multidisciplinary approach balancing infection control and graft preservation. Further research is needed to develop effective treatments for chronic norovirus infection in immunosuppressed populations."

Clinical • Chronic Kidney Disease • Glomerulonephritis • Infectious Disease • Transplantation

Management of Multiple Myeloma After Kidney Transplantation: A Close Collaboration Between Nephrology and Oncology (NKF-SCM 2025) - "He was treated with CyBorD followed by RVD (lenalidomide, bortezomib, and dexamethasone)...Renal function did not improve and he remained on HD.Results He underwent kidney transplantation with a living unrelated donor 3 years after initial presentation with basiliximab induction and maintenance immunosuppression of tacrolimus, mycophenolate sodium and prednisone...Bone marrow biopsy 44 months later revealed IgG Lambda MM and he was started on lenalidomide, Isatuximab, and dexamethasone for 1 year followed by lenalidomide and Isatuximab with good response...2019 2020 2021 2022 2023 2024 Cr 1.2-2.04 1.37-1.98 1.53-1.75 1.41-1.65 1.44-1.65 1.37-1.69 UPCR < 0.3 < 0.3 < 0.3 < 0.3 < 0.3 < 0.3 L LC nl nl nl 202.9 nl nl nl: normal.Conclusion Our case highlights the complexities and opportunities to manage patients with MM who undergo kidney transplantation with novel agents. It demonstrates the possibility of achieving long-term patient and graft survival with..."

Anemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukopenia • Multiple Myeloma • Nephrology • Novel Coronavirus Disease • Oncology • Transplantation

De Novo Proliferative Glomerulonephritis with Monoclonal IgG Deposits in kidney and pancreas allograft: Case report (NKF-SCM 2025) - "We present a case of De Novo PGNMID 10 years after renal and pancreas transplant.Methods A 49-year-old male with history of end stage renal disease secondary to T1DM s/p deceased donor kidney (2003) and pancreas (2009) transplant, maintained on a 2-drug immunosuppressive regimen with tacrolimus and myfortic, with excellent allograft function (creatinine of 1.3 mg/dl) and normal A1c of 5.1 presented for evaluation of hematuria and proteinuria on urinalysis with worsening allograft function in 2019...He was treated conservatively with lisinopril.Conclusion De novo PGNMID in the renal allograft is extremely rare with no standard treatment guidelines. Outcomes and prognosis remain poor in those without detectable clones, as in our patient. Despite treatment with Rituximab, he continues to have worsening renal allograft function and is under evaluation for a second renal transplant."

Case report • Clinical • Glomerulonephritis • Hepatology • Lupus Nephritis • Nephrology • Oncology • Type 1 Diabetes Mellitus

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Trial completion date: Dec 2027 ➔ Mar 2027 | Trial primary completion date: Dec 2025 ➔ Feb 2027

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation • HLA-B • HLA-C • HLA-DQB1 • HLA-DRB1

A Blood Stem Cell Transplant for Sickle Cell Disease (clinicaltrials.gov) - P1 | N=3 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Nov 2024 ➔ Mar 2025 | Trial primary completion date: Nov 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • Anemia • Bone Marrow Transplantation • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • Transplantation • CD4 • FOXP3 • HLA-B • HLA-C • HLA-DRB1